MX2018011177A - Agonistas de receptor de neuropéptido s (npsr). - Google Patents

Agonistas de receptor de neuropéptido s (npsr).

Info

Publication number
MX2018011177A
MX2018011177A MX2018011177A MX2018011177A MX2018011177A MX 2018011177 A MX2018011177 A MX 2018011177A MX 2018011177 A MX2018011177 A MX 2018011177A MX 2018011177 A MX2018011177 A MX 2018011177A MX 2018011177 A MX2018011177 A MX 2018011177A
Authority
MX
Mexico
Prior art keywords
neuropeptide
receptor
agonists
npsr
disorders
Prior art date
Application number
MX2018011177A
Other languages
English (en)
Inventor
Narayanan Sanju
Runyon Scott
Hassler Carla
SHINER Craig
Original Assignee
Res Triangle Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Triangle Inst filed Critical Res Triangle Inst
Publication of MX2018011177A publication Critical patent/MX2018011177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms

Abstract

Se proporcionan agonistas del receptor de neuropéptido S. Los agonistas NPS incluyen análogos peptidomiméticos que exhiben afinidad para y actividad en el receptor de neuropéptido S. Las moléculas pueden ser útiles en el tratamiento de trastornos, síndromes y condiciones mediadas por modulación del receptor de neuropéptido S tal como abuso de sustancia, narcolepsia, insomnio, obesidad, deterioro cognitivo, demencia, enfermedad de Alzheimer, trastorno de pánico, ansiedad generalizada, PTSD, fobias, esquizofrenia y como medicación de apoyo durante cualquier clase de programa cesación en terapia de comportamiento cognitivo, tal como adicción de fármaco, trastornos de alimentación y juegos de azar.
MX2018011177A 2016-04-04 2017-03-23 Agonistas de receptor de neuropéptido s (npsr). MX2018011177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662318042P 2016-04-04 2016-04-04
PCT/US2017/023762 WO2017176461A1 (en) 2016-04-04 2017-03-23 Neuropeptide s receptor (npsr) agonists

Publications (1)

Publication Number Publication Date
MX2018011177A true MX2018011177A (es) 2018-11-21

Family

ID=60000661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011177A MX2018011177A (es) 2016-04-04 2017-03-23 Agonistas de receptor de neuropéptido s (npsr).

Country Status (8)

Country Link
US (1) US11142546B2 (es)
EP (1) EP3440051B1 (es)
JP (1) JP7132125B2 (es)
CN (1) CN109153635B (es)
AU (2) AU2017246706B2 (es)
CA (1) CA3018344A1 (es)
MX (1) MX2018011177A (es)
WO (1) WO2017176461A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3018344A1 (en) 2016-04-04 2017-10-12 Research Triangle Institute Neuropeptide s receptor (npsr) agonists
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CN108863908B (zh) * 2018-04-24 2020-06-09 宿迁联盛科技股份有限公司 一种聚合型橡胶稳定剂中间体及其制备方法
EP4323340A2 (en) * 2021-04-13 2024-02-21 President and Fellows of Harvard College E3 ligase binders and uses thereof
CN114712484B (zh) * 2022-03-14 2023-07-04 中山大学 一种神经肽s在制备防治晕动症药物中的应用
KR20230140541A (ko) * 2022-03-28 2023-10-06 주식회사 비엔에이치리서치 약물의 전기생리학적 스크리닝 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3801562A (en) * 1970-11-19 1974-04-02 Rohm & Haas N-acylated peptides of amino aromatic acids and their derivatives
US3745202A (en) * 1971-03-17 1973-07-10 Us Interior Method of preparing an asymmetric membrane from a cellulose derivative
FI70597C (fi) 1979-04-06 1986-09-24 Carlsberg Biotechnology Ltd Foerfarande foer enzymatisk framstaellning av peptider
US4339535A (en) * 1979-08-27 1982-07-13 E. R. Squibb & Sons, Inc. Process for preparing antibiotic EM 4940
AU766219B2 (en) * 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
AU2001236485A1 (en) * 2000-01-21 2001-07-31 Mallinckrodt, Inc. Novel orthogonally protected amino acid chelators for biomedical applications
JP4771661B2 (ja) * 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
WO2005025554A2 (en) * 2003-09-09 2005-03-24 Japan Tobacco Inc. Dipeptidyl peptidase iv inhibitor
US7605289B2 (en) * 2005-06-17 2009-10-20 Amgen, Inc. Benzamide derivatives and uses related thereto
WO2007014258A2 (en) * 2005-07-22 2007-02-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Growth hormone secretagogues
US8957219B2 (en) * 2008-10-17 2015-02-17 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on endothelial lipase
CN101519430A (zh) * 2009-03-20 2009-09-02 中国农业大学 一类新型保幼激素合成抑制剂－苯丙-甘-亮三肽酰胺类似物
CN101519431A (zh) * 2009-03-20 2009-09-02 中国农业大学 一类含苯丙-甘-亮三肽片段的拟肽类保幼激素合成抑制剂
JP2015505297A (ja) * 2011-10-28 2015-02-19 ルーイ・ジェイ・ユ Ｎ−アシルジペプチド誘導体およびその使用
JP6381445B2 (ja) * 2011-12-08 2018-08-29 リサーチ トライアングル インスティテュート ニューロペプチドｓレセプター（ｎｐｓｒ）アンタゴニストの組成物および方法
CN104710508B (zh) * 2015-03-20 2017-11-28 兰州大学 基于内吗啡肽2和npff受体拮抗剂rf9的分叉型杂交肽及其合成方法和应用
CA3018344A1 (en) 2016-04-04 2017-10-12 Research Triangle Institute Neuropeptide s receptor (npsr) agonists

Also Published As

Publication number Publication date
EP3440051B1 (en) 2024-03-20
JP2019513704A (ja) 2019-05-30
EP3440051A4 (en) 2019-11-27
JP7132125B2 (ja) 2022-09-06
CN109153635B (zh) 2022-04-08
US20190092809A1 (en) 2019-03-28
AU2017246706B2 (en) 2020-09-17
CA3018344A1 (en) 2017-10-12
AU2020289743A1 (en) 2021-01-21
US11142546B2 (en) 2021-10-12
CN109153635A (zh) 2019-01-04
WO2017176461A1 (en) 2017-10-12
AU2017246706A1 (en) 2018-10-04
EP3440051A1 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
MX2018011177A (es) Agonistas de receptor de neuropéptido s (npsr).
Mrazek et al. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013
Zandi et al. Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
UA114704C2 (uk) Способи та лікарські засоби для лікування хвороби альцгеймера
MX356412B (es) Anticuerpos anti-kdr y metodos de uso.
MX2015008555A (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
WO2017176460A3 (en) Neuropeptide s receptor (npsr) agonists
DiSabella DUPLICATE: Cinnarizine: A Promising Agent for Migraine Prevention You May Never Get the Chance to Use
Smulevich et al. Nooklerin (deanoli aceglumas) in the treatment of astenic and cognitive disorders in patients with borderline psychopatological conditions
Enright et al. Forgiveness therapy in addictive disorders.
Kaleda Youth-onset schizophrenia: psychopathology, clinical presentation and therapy
Vázquez-Sanabria et al. Sustained improvement of fibromyalgia syndrome after electroconvulsive therapy for intractable depression
Malabaila et al. Psycho-Oncology in Brain Tumour Patients
Televca The immune process in the pathogenesis of tumors
Mijaljica Seborrhoeic dermatitis: 7 case reports
Yu Application of reiki on depression in nursing: a literature review
Godfrey et al. Inside the family meal: a thematic analysis of session two in Maudsley family-based treatment for anorexia nervosa
Ferreira et al. Anti-psychotics: To withdraw or not to withdraw?
Valeriani et al. 16. Presynaptic and postsynaptic inhibition in the human dorsal column nuclei
Ginory et al. EPA-0946-Assessment and treatment of psychiatric symptoms in patients with parkinson's disease
Fjukstad et al. Selective serotonin reuptake inhibitors, anti-psychotics and metabolic risk factors in schizophrenia and bipolar disorder
Branchi Beneficial and Adverse Consequences of Increased Brain Plasticity: the Interplay Among Serotonin, Susceptibility to the Environment and Depression
Koychev et al. EPA-0931-Acute ketamine challenge effects on visual information processing: implications for psychosis
Dragioti et al. Internet use among patients with psychotic disorder